End Brain Cancer Initiative releases free guide on tumor sequencing

The End Brain Cancer Initiative has published a free patient and caregiver guide on next-generation sequencing for brain tumors and cancers, with support from Jazz Pharmaceuticals and Servier. The guide is meant to help patients, caregivers and clinicians understand how biomarker testing can guide more targeted treatment decisions.

Why it matters: - Next-generation sequencing can help identify genetic changes that drive brain tumor growth. - The guide is designed to help patients and caregivers better understand testing options that may connect them with targeted therapies. - The resource aims to support more informed conversations between patients and medical teams.

What happened: - The End Brain Cancer Initiative released a free educational guide titled “Next-Generation Sequencing (NGS) Biomarker and Fusion Testing: Targeted Therapy for Brain Tumors/Cancers.” - Jazz Pharmaceuticals and Servier sponsored the guide. - The release was announced in Seattle on Nov. 10, 2026. - The guide is available online.

The details: - Next-generation sequencing is a laboratory technology that reads the genetic code of a patient’s tumor. - The testing looks for mutations, alterations or biomarkers in the DNA or RNA of cancer cells. - Those changes can drive tumor growth. - Doctors can use the results to match patients with treatments designed to target those changes. - Patients, caregivers, healthcare providers and members of the public can access the guide for free. - Kari Schroeder, EBCI’s Nurse Navigator and Clinical Trial Coordinator, is available at 425-436-8688 or Kari@EndBrainCancer.org for more information. - Jazz Pharmaceuticals is a global biopharma company focused on rare disease, cancer and sleep disorders. - Servier is a global oncology company governed by a non-profit foundation.

Between the lines: - The guide reflects growing use of biomarker-driven cancer care, where treatment selection is increasingly tied to tumor genetics. - EBCI is positioning the resource as an education tool for a patient group that often faces complex diagnostic and treatment decisions. - The sponsorship from two drug makers signals industry interest in expanding awareness of precision oncology.

What's next: - EBCI is directing patients and caregivers to the guide as a starting point for discussions about advanced diagnostics and treatment options. - The organization continues to focus on disease education, outreach and access to care for people with brain cancer, brain tumors and metastatic disease to the brain. - More information is available at EndBrainCancer.org.